Smithfield Bioscience Inc – FDA 483, Jul 15, 2022
Smithfield Bioscience Inc. in Cincinnati, OH, received a Form 483 with three observations related to its manufacturing of Heparin Sodium, USP finished API. The inspection revealed significant issues with inadequate investigations into out-of-specification results and environmental excursions, a repeat observation from a previous inspection. Additionally, the firm's environmental monitoring program was found to be unrepresentative of production conditions, and contract testing laboratories were not properly qualified.
ID · 3789f259-60b8-43fe-bd5b-6e377ac56d90
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.